May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Comparative Therapy Evaluation of Intravitreal Bevacizumab and Triamcinolone Acetonide on Persistent Diffuse Diabetic Macular Edema
Author Affiliations & Notes
  • M. Shimura
    Ophthalmology, NTT East Japan Tohoku Hosp, Sendai, Japan
  • T. Nakazawa
    Ophthalmology, Tohoku University Graduate School of Medicine, Sendai, Japan
  • K. Yasuda
    Ophthalmology, NTT East Japan Tohoku Hosp, Sendai, Japan
  • T. Shiono
    Ophthalmology, Shiono Eye Center, Sendai, Japan
  • T. Iida
    Ophthalmology, Fukushima Medical University, Fukushima, Japan
  • T. Sakamoto
    Ophthalmology, Kagoshima University, Kagoshima, Japan
  • K. Nishida
    Ophthalmology, Tohoku University Graduate School of Medicine, Sendai, Japan
  • Footnotes
    Commercial Relationships  M. Shimura, None; T. Nakazawa, None; K. Yasuda, None; T. Shiono, None; T. Iida, None; T. Sakamoto, None; K. Nishida, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 3513. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      M. Shimura, T. Nakazawa, K. Yasuda, T. Shiono, T. Iida, T. Sakamoto, K. Nishida; Comparative Therapy Evaluation of Intravitreal Bevacizumab and Triamcinolone Acetonide on Persistent Diffuse Diabetic Macular Edema. Invest. Ophthalmol. Vis. Sci. 2008;49(13):3513. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To compare the effect of intravitreal injection of bevacizumab, an anti-VEGF antibody, with that of triamcinolone acetonide (TA), a corticosteroid for reduction of diabetic macular edema (DME)

Methods: : Prospective, comparative interventional case series. Twenty-eight eyes of 14 patients with bilateral DME participated in this study. In each patient, one eye received intravitreal injection of 4 mg TA and the other eye received 1.25 mg bevacizumab. The clinical course of best corrected visual acuity (VA) with logMAR chart and averaged foveal thickness (FT) using optical coherence tomography was monitored for up to 24 weeks after the injection. The procedures conformed to the tenets of the Declaration of Helsinki.

Results: : Before the injection, FT and VA were 522.3 ± 91.3 µm and 0.64 ± 0.28 in the TA-injected eye, and 527.6 ± 78.8 µm and 0.61 ± 0.18 in the bevacizumab-injected eye, respectively; there was no significant difference between the eyes. One week after the injection, both eyes showed significant regression of macular edema. The TA-injected eye (342.6 ± 85.5 µm and 0.33 ± 0.21) showed significantly better results than the bevacizumab-injected eye (397.6 ± 103.0 µm and 0.37 ± 0.17). However, both eyes showed the recurrence of macular edema with time, even at 24 weeks. TA (410.4 ± 82.4 µm and 0.47 ± 0.25) kept better results than bevacizumab (501.6 ± 92.5 µm and 0.61 ± 0.17).

Conclusions: : With the generally used-concentration, intravitreal injection of TA brought better results of reducing DME than that of bevacizumab, suggesting that the pathogenesis of DME is not only due to VEGF-dependency, but is also due to corticosteroid-dependent mechanisms.

Keywords: diabetic retinopathy • edema • drug toxicity/drug effects 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×